icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
nQeX3yGbEMbVC58d
Listen
